Seaweed-derived Rhamnan Sulfate and Vascular Function

Launched by UNIVERSITY OF TEXAS AT AUSTIN · Dec 6, 2022

Keywords

ClinConnect Summary

This clinical trial is investigating whether a supplement derived from seaweed, known as rhamnan sulfate, can improve blood vessel health in middle-aged and older adults who have at least one risk factor for cardiovascular disease, such as high cholesterol, high blood pressure, obesity, or elevated blood sugar levels. The researchers believe that taking this supplement for a short period could help improve important markers of how well the blood vessels function.

To participate in the trial, individuals must be middle-aged or older and have at least one of the mentioned risk factors for cardiovascular disease. They should also have a body mass index (BMI) of less than 40. However, people with certain health issues like digestive or kidney disorders, those who are pregnant or breastfeeding, or those who engage in very intense physical activity more than three times a week are not eligible to join. Participants can expect to take the supplement and undergo assessments to see how their vascular health changes throughout the study. This trial is currently looking for volunteers, and everyone is welcome to apply, regardless of gender.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • at least one risk factor for cardiovascular disease (e.g., dyslipidemia, hypertension, obesity, impaired fasting glucose)
• • a BMI of \<40 kg/m2
• Exclusion Criteria:
• • gastrointestinal disorders and/or renal disease
• • pregnancy or lactation
• • strenuous physical activity (\>3 times/week)
• • alcohol abuse